Recombinant coagulation factor VIIa (rFVIIa) is generally accepted for treatment of patients with inhibitor-complicated hemophilia. Recently, rFVIIa variants with a specific enhancement of the tissue factor (TF)-independent proteolytic activity have been described.
Thrombosis and Hemostasis Laboratory, G03.647, Department of Hematology, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. j.a.lisman@azu.nl
